What did the early CTX310 study measure?

On November 9, 2026, CRISPR Therapeutics announced Phase 1b results for CTX310, reporting changes in blood lipid measures among participants with severe hypertriglyceridemia.

What to check after reading

When reading an early-stage company announcement, record the trial phase, comparison, measured outcomes, and follow-up window.

Source

CRISPR Therapeutics announcement ↗

Calendar dates show when a case was added or scheduled. For event dates, check the original source.